Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10592640 | Bioorganic & Medicinal Chemistry Letters | 2014 | 10 Pages |
Abstract
Following a hit-finding and lead optimization programme against the EP4 receptor (EP4R), five structurally diverse series of hit compounds were discovered using a combination of virtual screening methods. The most favoured hit, compound 6, was demonstrated to be a competitive antagonist of the EP4R. Compound 73 was identified following several rounds of optimization, which centred on improving both the primary EP4R affinity and selectivity against the related EP2R as well as the aqueous solubility. The work culminated in the identification of PGN-1531, the sodium salt of 73, which showed a marked improvement in solubility (>10Â mg/mL). PGN-1531 is a potent and selective antagonist at EP4Rs in vitro and in vivo, with the potential to alleviate the symptoms of migraine that result from cerebral vasodilatation.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jon Sutton, David E. Clark, Christopher Higgs, Marcel J. de Groot, Neil V. Harris, Andrea Taylor, Peter M. Lockey, Karen Maubach, Amanda Woodrooffe, Richard J. Davis, Robert A. Coleman, Kenneth L. Clark,